Akebia Therapeutics (AKBA) News Today $1.95 -0.09 (-4.41%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$1.96 +0.02 (+0.77%) As of 08:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025March 25 at 8:00 AM | globenewswire.comAkebia Therapeutics, Inc. Announces Underwritten Public Offering of Common StockMarch 21, 2025 | nasdaq.comAkebia's Valuation Looks Stretched Despite Auryxia's Loss Of ExclusivityMarch 21, 2025 | seekingalpha.comWhy Akebia Therapeutics Inc. (AKBA) Went Down On Thursday?March 21, 2025 | msn.comAkebia 25M share Spot Secondary priced at $2.00March 20, 2025 | markets.businessinsider.comAkebia Therapeutics (NASDAQ:AKBA) Shares Up 11.2% - Here's What HappenedAkebia Therapeutics (NASDAQ:AKBA) Shares Up 11.2% - Should You Buy?March 20, 2025 | marketbeat.comAkebia announces common stock offering, no amount givenMarch 20, 2025 | markets.businessinsider.comJOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionMarch 20, 2025 | benzinga.comAkebia Therapeutics Announces Pricing of Public Offering of Common StockMarch 19, 2025 | globenewswire.comIs Akebia Therapeutics (AKBA) the Best Stock to Invest in for a Stock Market Game?March 19, 2025 | insidermonkey.comAkebia Therapeutics Announces Proposed Public Offering of Common StockMarch 19, 2025 | globenewswire.comAkebia Therapeutics (NASDAQ:AKBA) Hits New 52-Week High - What's Next?Akebia Therapeutics (NASDAQ:AKBA) Hits New 52-Week High - Still a Buy?March 19, 2025 | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Upgraded at StockNews.comStockNews.com upgraded Akebia Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday.March 18, 2025 | marketbeat.comAkebia Therapeutics' (AKBA) "Buy" Rating Reiterated at HC WainwrightMarch 17, 2025 | americanbankingnews.comUS$7.83 - That's What Analysts Think Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Worth After These ResultsMarch 16, 2025 | finance.yahoo.comAkebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call TranscriptMarch 15, 2025 | seekingalpha.comAkebia Therapeutics Target of Unusually Large Options Trading (NASDAQ:AKBA)Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) was the recipient of some unusual options trading on Friday. Investors bought 3,386 call options on the stock. This represents an increase of 303% compared to the typical daily volume of 841 call options.March 15, 2025 | marketbeat.comPiper Sandler Forecasts Strong Price Appreciation for Akebia Therapeutics (NASDAQ:AKBA) StockPiper Sandler raised their target price on Akebia Therapeutics from $4.00 to $6.00 and gave the company an "overweight" rating in a research note on Friday.March 15, 2025 | marketbeat.comAkebia Therapeutics' (AKBA) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and set a $7.50 target price on shares of Akebia Therapeutics in a research note on Friday.March 15, 2025 | marketbeat.comAkebia price target raised to $6 from $4 at Piper SandlerMarch 14, 2025 | markets.businessinsider.comAkebia Therapeutics (NASDAQ:AKBA) Posts Earnings Results, Misses Expectations By $0.05 EPSAkebia Therapeutics (NASDAQ:AKBA - Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.05).March 14, 2025 | marketbeat.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | insidermonkey.comQ4 2024 Akebia Therapeutics Inc Earnings CallMarch 14, 2025 | uk.finance.yahoo.comAkebia reports Q4 EPS (10c) vs 0c last yearMarch 13, 2025 | markets.businessinsider.comAkebia slumps after Q4 earnings missMarch 13, 2025 | msn.comAkebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress UpdateMarch 13, 2025 | globenewswire.comAkebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business HighlightsMarch 6, 2025 | finance.yahoo.comAkebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business HighlightsMarch 6, 2025 | globenewswire.comAkebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.comStockNews.com cut Akebia Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday.March 6, 2025 | marketbeat.comAkebia Therapeutics (AKBA) to Release Earnings on ThursdayAkebia Therapeutics (NASDAQ:AKBA) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 6, 2025 | marketbeat.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 4, 2025 | globenewswire.comAkebia Therapeutics (NASDAQ:AKBA) Raised to Hold at StockNews.comStockNews.com raised shares of Akebia Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday.February 26, 2025 | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Cut to Sell at StockNews.comStockNews.com lowered shares of Akebia Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday.February 18, 2025 | marketbeat.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Large Drop in Short InterestAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 14,450,000 shares, a decline of 19.7% from the January 15th total of 17,990,000 shares. Based on an average daily volume of 2,260,000 shares, the short-interest ratio is currently 6.4 days.February 15, 2025 | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Raised to "Hold" at StockNews.comStockNews.com raised Akebia Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday.February 10, 2025 | marketbeat.comAkebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues DeclineFebruary 10, 2025 | seekingalpha.comInsider Selling: Akebia Therapeutics, Inc. (NASDAQ:AKBA) CAO Sells 30,202 Shares of StockFebruary 5, 2025 | insidertrades.comInsider Selling: Akebia Therapeutics, Inc. (NASDAQ:AKBA) CAO Sells 30,202 Shares of StockAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) CAO Richard C. Malabre sold 30,202 shares of the company's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $2.10, for a total transaction of $63,424.20. Following the completion of the sale, the chief accounting officer now owns 280,248 shares of the company's stock, valued at approximately $588,520.80. The trade was a 9.73 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.February 4, 2025 | marketbeat.comSteven Keith Burke Sells 50,506 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) StockAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) SVP Steven Keith Burke sold 50,506 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $2.10, for a total transaction of $106,062.60. Following the completion of the transaction, the senior vice president now directly owns 816,234 shares of the company's stock, valued at $1,714,091.40. This trade represents a 5.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.February 4, 2025 | marketbeat.comNicholas Grund Sells 55,621 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) StockAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) insider Nicholas Grund sold 55,621 shares of Akebia Therapeutics stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $2.10, for a total value of $116,804.10. Following the transaction, the insider now directly owns 442,579 shares in the company, valued at approximately $929,415.90. The trade was a 11.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.February 4, 2025 | marketbeat.comInsider Selling: Akebia Therapeutics, Inc. (NASDAQ:AKBA) CEO Sells 144,250 Shares of StockAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) CEO John P. Butler sold 144,250 shares of Akebia Therapeutics stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $2.10, for a total transaction of $302,925.00. Following the sale, the chief executive officer now directly owns 2,604,330 shares of the company's stock, valued at approximately $5,469,093. This trade represents a 5.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.February 4, 2025 | marketbeat.comAkebia Therapeutics' chief accounting officer sells $63,424 in stockFebruary 4, 2025 | msn.comAkebia Therapeutics' chief commercial officer sells $116,804 in stockFebruary 4, 2025 | msn.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 4, 2025 | globenewswire.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest UpdateAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 16,680,000 shares, an increase of 18.6% from the December 31st total of 14,070,000 shares. Based on an average daily volume of 2,100,000 shares, the days-to-cover ratio is presently 7.9 days.January 31, 2025 | marketbeat.comH.C. Wainwright maintains Akebia stock Buy rating, $7.50 targetJanuary 24, 2025 | msn.comAkebia Therapeutics (NASDAQ:AKBA) Trading 10.9% Higher - Time to Buy?Akebia Therapeutics (NASDAQ:AKBA) Stock Price Up 10.9% - Time to Buy?January 23, 2025 | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Trading Down 4.4% - What's Next?Akebia Therapeutics (NASDAQ:AKBA) Stock Price Down 4.4% - Time to Sell?January 23, 2025 | marketbeat.comAkebia Therapeutics' (AKBA) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $7.50 price target on shares of Akebia Therapeutics in a research note on Thursday.January 23, 2025 | marketbeat.comAkebia price target raised to $10 from $5 at BTIGJanuary 22, 2025 | markets.businessinsider.com Remove Ads Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address AKBA Media Mentions By Week AKBA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKBA News Sentiment▼0.010.79▲Average Medical News Sentiment AKBA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKBA Articles This Week▼133▲AKBA Articles Average Week Remove Ads Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TVTX News JANX News IRON News AGIO News APGE News MESO News VERA News GLPG News KNSA News SDGR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKBA) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKBA Stock Free AKBA Stock Alerts